Holen Sie sich die Stockscreener-App
2.89
0.52%
0.00
Schlusskurs vom Vortag:
$2.89
Offen:
$2.84
24-Stunden-Volumen:
3.12M
Relative Volume:
1.18
Marktkapitalisierung:
$617.15M
Einnahmen:
$12.87M
Nettoeinkommen (Verlust:
$-114.34M
KGV:
-3.3426
EPS:
-0.8646
Netto-Cashflow:
$-79.23M
1W Leistung:
+13.48%
1M Leistung:
+63.20%
6M Leistung:
+17.61%
1J Leistung:
-2.19%
1-Tages-Spanne:
$2.72
$2.935
1-Wochen-Bereich:
$2.555
$3.24
52-Wochen-Spanne:
$1.05
$4.32
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Firmenname
Taysha Gene Therapies Inc
Sektor
Branche
Telefon
(214) 612-0000
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Vergleichen Sie TSHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
2.875 | 508.75M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
ONC
Beigene Ltd Adr
|
238.88 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.54 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
595.92 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.89 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-01 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-03-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-03-01 | Eingeleitet | Wells Fargo | Overweight |
| 2022-02-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | Guggenheim | Buy |
| 2021-07-16 | Eingeleitet | Needham | Buy |
| 2021-06-24 | Eingeleitet | Truist | Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-06-09 | Eingeleitet | Wedbush | Outperform |
| 2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Fortgesetzt | Jefferies | Buy |
| 2021-02-24 | Eingeleitet | William Blair | Outperform |
| 2021-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-19 | Eingeleitet | Goldman | Buy |
| 2020-10-19 | Eingeleitet | Jefferies | Buy |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
FY2025 EPS Estimates for TSHA Lifted by Cantor Fitzgerald - Defense World
Taysha, FDA agree on next steps of REVEAL trial for Rett gene therapy - Rett Syndrome News
Taysha outlines expedited pivotal trial start for TSHA-102 following FDA alignment - MSN
Canaccord Genuity Group Forecasts Strong Price Appreciation for Taysha Gene Therapies (NASDAQ:TSHA) Stock - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 6.1% Following Analyst Upgrade - Defense World
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates - MSN
Expert Outlook: Taysha Gene Therapies Through The Eyes Of 6 Analysts - Benzinga
Taysha Gene Therapies (TSHA) Sees Price Target Raised by Canaccord Genuity | TSHA Stock News - GuruFocus
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2025 Earnings Call Transcript - Insider Monkey
Canaccord Boosts Price Target for Taysha Gene Therapies (TSHA) | - GuruFocus
Taysha Gene Therapies Reports First Quarter 2025 Financial Resul - GuruFocus
Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Call Highlights: Promising Clinical Progress ... - Yahoo Finance
Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Call Highlight - GuruFocus
Taysha Gene Therapies Advances in Rett Syndrome Trials - TipRanks
Baird maintains Outperform on Taysha stock, reiterates $7 target By Investing.com - Investing.com Nigeria
Transcript : Taysha Gene Therapies, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Taysha Gene Therapies’ Positive Q1 2025 Earnings Call - TipRanks
Baird maintains Outperform on Taysha stock, reiterates $7 target - Investing.com
Earnings call transcript: Taysha Gene Therapies Q1 2025 sees stock surge on earnings beat - Investing.com Nigeria
Taysha Gene Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Taysha Gene Therapies Q1 2025 Earnings Call Transcript - MarketBeat
Taysha (TSHA) Q1 Revenue Exceeds Expectations, Progresses with C - GuruFocus
Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Taysha (TSHA) Q1 Revenue Exceeds Expectations, Progresses with Clinical Trials | TSHA Stock News - GuruFocus
Taysha Gene Therapies Q1 2025 Financial Results - TradingView
Taysha's Rett Syndrome Gene Therapy Gains FDA Support: Key Trial Design Approved Without Phase Meeting - Stock Titan
Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Acquired by Hsbc Holdings PLC - Defense World
Taysha Gene Therapies (TSHA) to Release Quarterly Earnings on Thursday - Defense World
Wells Fargo & Company MN Has $179,000 Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Barclays PLC Grows Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Mariner LLC Has $101,000 Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15 - The Manila Times
Taysha Gene Therapies to Release First Quarter 2025 - GlobeNewswire
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know - MSN
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Benzinga
Taysha Gene Therapies Inc (NASDAQ: TSHA) Up 40.46% This Year: What To Expect Next - Stocksregister
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 9.3% – Should You Buy? - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Price Target from Analysts - Defense World
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Taysha Gene Therapies (TSHA) Grants Employee Stock Option Under Inducement Plan | TSHA Stock News - GuruFocus
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Li - GuruFocus
BMO Capital Markets slashes price target on Taysha Gene Therapies Inc [TSHA] – find out why. - dbtnews.com
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | TSHA Stock News - GuruFocus
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies (TSHA) Gains Analyst Support with Promising Gene Therapy | TSHA Stock News - GuruFocus
Buying Buzz: Taysha Gene Therapies Inc [TSHA] 10% Owner Manning Paul B purchases 1,333,333 shares of the company – Knox Daily - knoxdaily.com
Anchoring Your Portfolio: Is TSHA Stock a Safe Harbor? - investchronicle.com
60,000 Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Bought by LPL Financial LLC - Defense World
Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
8.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):